Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology.
暂无分享,去创建一个
Qiong Li | Guangyuan Sun | Shiyuan Liu | Qiong Li | Shiyuan Liu | Wenting Tu | Guangyuan Sun | L. Fan | Yun Wang | Yi Xia | Y. Guan | Di Zhang | Zhaobin Li | Li Fan | Yu Guan | Yi Xia | Wenting Tu | Yun Wang | Di Zhang | Zhaobin Li
[1] Benjamin Haibe-Kains,et al. Vulnerabilities of radiomic signature development: The need for safeguards. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] Jie Tian,et al. Radiomics signature: a biomarker for the preoperative discrimination of lung invasive adenocarcinoma manifesting as a ground-glass nodule , 2018, European Radiology.
[3] D. Dong,et al. Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer , 2017, Translational oncology.
[4] John Quackenbush,et al. Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer. , 2017, Cancer research.
[5] Chintan Parmar,et al. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non–Small Cell Lung Cancer , 2017, The Journal of Nuclear Medicine.
[6] D. Ikeda,et al. Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways , 2017, Clinical Cancer Research.
[7] Brett W Carter,et al. Predicting Malignant Nodules from Screening CTs. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] Samuel H. Hawkins,et al. Predicting Malignant Nodules from Screening CT Scans , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] Y. Liu,et al. Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas. , 2016, Clinical lung cancer.
[10] Jie Tian,et al. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy , 2016, 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[11] A. Nicholson,et al. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part‐Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] Ying Liu,et al. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma. , 2016, Radiology.
[13] Paul Kinahan,et al. Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.
[14] Steven D Chang,et al. Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities , 2015, Science Translational Medicine.
[15] P. Lambin,et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] X. Chen,et al. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations , 2015, European Radiology.
[17] G. Liu,et al. Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma , 2014, Journal of thoracic imaging.
[18] P. Lambin,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.
[19] Mark J. Ratain,et al. Tumour heterogeneity in the clinic , 2013, Nature.
[20] Robert Brian Jenkins,et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] G. Giaccone,et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.
[22] P. Souquet,et al. Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes , 2013, Lung.
[23] M. Ladanyi,et al. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[24] J. Goo,et al. Imaging Characteristics of Stage I Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and Survival , 2013, Korean journal of radiology.
[25] Qinghua Zhou,et al. Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer , 2013, PloS one.
[26] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[27] Matthew D. Wilkerson,et al. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..
[28] M. Socinski,et al. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance? , 2008, The oncologist.
[29] Kikuya Kato,et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib , 2008, Cancer science.
[30] H. Sasaki,et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer , 2008, Journal of Cancer Research and Clinical Oncology.
[31] M. Ladanyi,et al. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.
[32] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[33] J. Mesirov,et al. Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data , 2003, Machine Learning.
[34] T. Nagayasu,et al. Title: Analysis of intra-tumor heterogeneity of EGFR mutations in mixed-type lung adenocarcinoma , 2019 .
[35] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[36] Haikuo Zhang,et al. Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors , 2016 .
[37] Massimo Bellomi,et al. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer , 2015, European Radiology.